Furthermore, the up-regulation of EMT-related transcription factors, such as ZEB1, ZEB2, SNAIL1, Slug, and TWIST has been observed in GBM patients following treatment with bevacizumab, a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF).78 This evidence concerns the gene SNAI1 and glioblastoma.